Full Breakdown
AI-Driven mRNA Vaccine Offers Hope for Canine Cancer Treatment
3/16/2026, 4:06:14 PM
The Journey to a Personalized Cancer Vaccine
In 2024, Sydney tech entrepreneur Paul Conyngham faced a personal crisis when his dog, Rosie, was diagnosed with cancer. After unsuccessful treatments involving chemotherapy and surgery, Conyngham sought alternative solutions. Utilizing artificial intelligence, he developed a custom mRNA cancer vaccine with assistance from Australian scientists at the University of New South Wales (UNSW). Conyngham, an electrical and computing engineer and cofounder of Core Intelligence Technologies, leveraged AI tools like OpenAI's ChatGPT and Google’s DeepMind AlphaFold to guide his research and treatment plan.
After reaching out to UNSW, Conyngham financed Rosie’s genomic sequencing and collaborated with researchers, including Pall Thordarson, director of UNSW’s RNA Institute. Thordarson utilized the genomic data to create a bespoke mRNA vaccine in under two months. This marked a significant milestone, as it was the first personalized cancer vaccine designed specifically for a dog. Thordarson noted, “This is still at the frontier of where cancer immunotherapeutics are—and ultimately, we’re going to use this for helping humans.”
Treatment Outcomes and Implications
Rosie received her initial vaccine injection in December 2024, followed by a booster in February 2025. The treatment has led to a notable reduction in the size of her tumors, significantly improving her quality of life. Conyngham expressed cautious optimism, stating, “I’m under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life.” Despite the positive outcomes, some tumors have not responded to the vaccine, indicating that while the treatment has been beneficial, it is not a definitive cure.
Broader Impact of AI in Medicine
Rosie's case has garnered attention in both the tech and medical communities, highlighting the potential of AI to revolutionize treatment approaches. Matt Shumer, cofounder and CEO of OthersideAI, remarked on social media about the implications of such advancements, suggesting that they could transform previously dire diagnoses into manageable conditions. Thordarson emphasized that Rosie’s experience illustrates how technology can “democratize” the process of designing cancer vaccines, potentially paving the way for similar innovations in human medicine.
Criticism and Caution
While the advancements in personalized medicine are promising, experts caution that the field is still evolving. The success of Rosie’s treatment does not guarantee similar outcomes for all cases, and the long-term efficacy of mRNA vaccines in veterinary medicine remains to be fully understood. Thordarson acknowledged the uncertainty, stating that while Rosie’s treatment has extended her life, it does not eliminate the challenges posed by her cancer.
Verbatim Quotes
- “This is the first time a personalized cancer vaccine has been designed for a dog,” — Pall Thordarson, Director, UNSW RNA Institute
- “In December she had low energy because the tumors were creating a huge burden for her,” — Paul Conyngham, Entrepreneur
- “Expect more stories like this, each sounding increasingly more insane.” — Matt Shumer, CEO, OthersideAI
Rosie's journey not only showcases the intersection of technology and veterinary medicine but also raises questions about the future of personalized treatments in both animals and humans.
